The Manila Times2d
GSK's Omjjara (momelotinib) approved in Singapore as the first treatment indicated for myelofibrosis patients with anaemia
Approval is for use in myelofibrosis patients with moderate to severe anaemia who are JAK-naive or previously treated with ...
pharmaphorum2d
After FDA setback, Ipsen gets first OK for rare disease drug palovarotene
Ipsen meanwhile also has another FOP candidate in its portfolio via its $535 million agreement with Blueprint in 2019 for BLU-782, an ALK2 inhibitor. FOP is caused by a mutation in the gene for ...
pharmaphorum3d
Ipsen's rare disease drug palovarotene knocked back in EU
Ipsen, meanwhile, also has another FOP candidate in its portfolio via its $535 million agreement with Blueprint in 2019 for BLU-782, an ALK2 inhibitor.
Yahoo Finance2d
Incyte Corporation (INCY)
After hours: March 14 at 5:13:30 p.m. EDT Loading Chart for INCY ...